ST吉药(300108) - 2021 Q4 - 年度财报

Financial Performance - The company's operating revenue for 2021 was ¥684,752,355.71, an increase of 5.58% compared to ¥648,546,128.84 in 2020[20] - The net profit attributable to shareholders for 2021 was a loss of ¥451,317,877.99, representing an increase in loss of 18.67% from a loss of ¥380,305,063.00 in 2020[20] - The total profit amounted to -¥463,682,133.25, a decrease of 12.17% year-on-year[39] - The company reported a total revenue of ¥682,752,097.72 after deducting certain amounts, compared to ¥646,653,766.20 in 2020[22] - Total revenue for 2021 reached ¥684,752,355.71, representing a year-on-year increase of 5.58% compared to ¥648,546,128.84 in 2020[41] Cash Flow and Assets - The net cash flow from operating activities improved significantly to ¥33,159,137.37, a 123.39% increase from a negative cash flow of ¥141,792,383.33 in 2020[20] - The total assets at the end of 2021 were ¥2,414,668,261.93, a decrease of 11.87% from ¥2,739,752,697.28 at the end of 2020[20] - The company reported a net decrease in cash and cash equivalents of ¥8,196,964.75, an improvement of 54.51% compared to the previous year[59] - Operating cash inflow totaled ¥602,422,300.78 in 2021, down 16.90% from ¥724,950,200.70 in 2020[58] Shareholder and Dividend Information - The company plans not to distribute cash dividends or issue bonus shares for the year[5] - The company’s profit distribution policy was executed in accordance with its articles of association, ensuring transparency and protection of minority shareholders' rights[120] - The company did not distribute cash dividends or issue bonus shares for the reporting period due to negative distributable profits, ensuring long-term interests of all shareholders[120] Operational Challenges - The company faced significant operational impacts due to severe liquidity shortages, leading to overdue loans and multiple lawsuits[4] - The company is currently involved in multiple lawsuits due to overdue debts and defaults on loans from multiple financial institutions[158] - The company is expected to provide updates on its financial strategies in response to these legal challenges[158] Research and Development - The company is currently developing one new drug, indicating ongoing investment in research and development[35] - Research and development expenses for 2021 were ¥16,631,400.91, reflecting a 1.24% increase from ¥16,427,118.51 in 2020[53] - R&D investment amounted to ¥11,264,141.84 in 2021, representing 1.64% of operating revenue, a decrease from 2.36% in 2020[56] Market and Product Information - The company operates in the pharmaceutical industry, which is increasingly important due to the aging population in China, with 264 million people aged 60 and above[33] - The pharmaceutical sector contributed ¥473,067,414.23, accounting for 69.09% of total revenue, with an 8.16% increase from ¥437,357,587.39 in 2020[41] - The company’s pharmaceutical segment includes various dosage forms, such as tablets, capsules, and injections, highlighting its diverse product offerings[35] Governance and Compliance - The company strictly adheres to corporate governance regulations, ensuring compliance with laws and enhancing operational standards for sustainable growth[78] - The board of directors consists of 5 members, including 2 independent directors, fulfilling legal requirements for governance structure[79] - The company emphasizes transparency in information disclosure, ensuring all shareholders have equal access to relevant information[80] Legal and Financial Issues - The company is involved in multiple lawsuits due to overdue debts, including cases with China Minmetals and Nanjing Bank, with amounts of 4,511.54 million and 1,545.15 million respectively[156] - The company has acknowledged the ongoing execution of legal proceedings related to its financial obligations[156] - Ji Pharmaceutical Holdings is actively working to address its debt issues and is in discussions with creditors to find resolutions[162] Employee and Management Information - The total number of employees at the end of the reporting period was 1,166, including 9 from the parent company and 1,157 from major subsidiaries[117] - The total remuneration paid to the board of directors, supervisors, and senior management was 2.5269 million yuan in 2021[101] - The company conducted weekly training sessions for employees on production skills and safety knowledge[119]